Table 2 Serum symmetric dimethylarginine (SDMA) measured in healthy horses (non-AKI group), horses at risk of acute kidney injury (high-risk group; divided into horses with colic and horses treated with NSAIDs and gentamicin), and horses with clinically manifest acute kidney injury (AKI group)
Parameter | Non-AKI group (n = 30) | High-risk group (n = 30) | AKI group (n = 11) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Colic (n = 10) | NSAIDs (n = 10) | Gentamicin (n = 10) | All | |||||||||||||||
Min–max | Me (Q1–Q3) | n’ | Min–max | Me (Q1–Q3) | n’ | Min–max | Me (Q1–Q3) | n’ | Min–max | Me (Q1–Q3) | n’ | Min–max | Me (Q1–Q3) | n’ | Min–max | Me (Q1–Q3) | n’ | |
SDMA (µg/dL) | 10–18 | 12 (11–14) | 2 | 6–18 | 12.5 (10.25–14.5) | 2 | 9–14 | 11 (9.25–11.75) | 0 | 12–15 | 13 (12–13.75) | 0 | 6–18 | 12 (11–13) | 2 | 19–62 | 20 (20–37) | 11 |